[go: up one dir, main page]

TW426673B - Novel benzoylguanidine derivatives, processes for preparing them and their use in the preparation of pharmaceutical compositions - Google Patents

Novel benzoylguanidine derivatives, processes for preparing them and their use in the preparation of pharmaceutical compositions Download PDF

Info

Publication number
TW426673B
TW426673B TW086100385A TW86100385A TW426673B TW 426673 B TW426673 B TW 426673B TW 086100385 A TW086100385 A TW 086100385A TW 86100385 A TW86100385 A TW 86100385A TW 426673 B TW426673 B TW 426673B
Authority
TW
Taiwan
Prior art keywords
alkyl
refers
general formula
substituted
group
Prior art date
Application number
TW086100385A
Other languages
English (en)
Inventor
Erich Buerger
Christian Eickmeier
Otto Roos
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Application granted granted Critical
Publication of TW426673B publication Critical patent/TW426673B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (1)

  1. 42667 3, 第86100385號專利申請案 中文申請專利範圍（89年11月) A8 BS C8 D8
    申請專利範圍 公 本 1 ·—種通式（I)之^·衍 修正
    z. -B
    (l) 其中 R々RrSOr ; A指
    N— {請先聞讀背面之注意事項再填寫本頁} .裝 ;〇仏 B指選自（-CHr)A-CO-之群，其中a代表丨至4間之整數； R2指選自下示之群：CN6••烷基， 苯基’其視需要被選自CN 4 -烷氧基，羥基，鹵素， 卣-Cw烷基，二.Cw-烷胺基，二-q.4-烷胺基 烷基，及CU4-烷基之群所取代， 呋喃基，其視需要可被一個CV4-烷基取代’ ρ塞吩基，说峻基，？比p各基， 為基’其視需要可被一個齒素取代’ 及-NR5^6， R3指(^.4-烷基； r5指cN4-烷基； r6指cv4-烷基》 本紙張尺度適用中國國家楯準（CNS ) A4規格（210X297公釐） -訂. 經濟部中央標準局貞工消費合作社印装 42667 3 A8 BS C8
    經濟部中央梂準局舅工消費合作社印製 2*根據申請專利範圍第丨項之通式（τ)芊醯基胍衍生物，其 中 R1 指 Me- S〇2·; A指
    B指選自（-CHr)a及-CO-之群，其中a代表1至4間之整數； R2指選自下示之群：C|4_烷基， 苯基’其视需要被選自甲氧基，羥基，氟，cf3，二甲 胺基’二甲胺基甲基，及甲基之群所取代， 呋喃基，其視需要可被一個甲基取代， »塞吩基，吡啶基，吡咯基， 萬基，其視需要可被一個氟取代， 及二甲胺基。 3·根據申請專利範固第丨或2項之通式（1)芊醯基胍衍生物， 其中 指Me-SOr ; A指 /~Λ —/一； / -2- --------—裝------訂-----叫線 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適財關家料（CNS > ( 2丨0X297公A ) 4266 7 3, 8 8 8 8 abcd 六、申請專利範圍 Β 指選自-CHr，-CH2-CHrl-CO-之群； 112指選自下示之群：CM-烷基， 呋喃基，其視需要被一個甲基取代， p塞吩基，p比这基，p比洛基1及二甲胺基。 4.根據申請專利範圍第1或2項之通式（I)芊醯基胍衍生物 其中 R^Me-SOr ; A指 B 指-C0- ; R 2指選自咬喃基，4吩基及说攻基之群 5. —種製備通式（I)化合物的方法 0
    OC)t 0) (請先M讀背面之注意事項再填寫本頁〕 經濟部中央標準局貝工消費合作社印茉 其特點在於由通式（II)之苯甲酸衍生物 0
    Ζλ 0〇〇 本紙伕尺度適用中國國家標準（CNS ) Α4说格（210Χ297公嫠） CXI) 經濟部中央榡準局貝工消費合作社印製 42667 3 Λ Α8 Β8 Cg ______D8_ 六、申請專利範圍 (其中p指離核脫離基團） 在可進行親核取代的條件下與通式（III)化合物反應， H23AQ i ((III) 其中Q指可以親核試劑取代的脫離基， 再由所得通式（IV)苯甲酸衍生物
    (IVJ 她 於第一步驟中懸浮於合適的溶劑内*並與N -甲基嗎啉及 羰基二咪唑（CDI)反應’再於第二步驟中，與鹼溶解或懸 浮於合適無水溶劑内的混合物合併，與胍鹽反應。 6.根據申請專利範囷第5項之方法，其特點還在於將所得通 式（IV)苯甲酸衍生物於第一步騾懸浮於無水溶劑内。 7·根據中請專利範圍第6項之方法*其中該第一步驟之無水 溶劑是二甲基甲醯胺。 8·根據申請專利範圍第5項之方法，其特點還在於將所得通 式（IV)苯甲酸衍生物於第二步騾中與氫化鈉溶解或懸浮於 合適無水溶劑内之混合物合併β 根據申請專利範圍第8項之方法，其中該第一步驟之無水 溶劑是二甲基f醯胺。 本紙張尺度適用中國國家梂準（CNS )八4说格（210X297公釐） ---------^-裝------订------1·^ t锖先閲讀背面之注意事項存填寫本頁) 4266 7 3, A8 B8 C8 D8 六、申請專利範圍 10. 根據申請專利範圍第5項之方法，其中與所製得笨甲酸衍 生物反應的胍鹽是胍鹽酸鹽》 11. 一種具Na+/H+交換抑制作用之醫藥组合物，其包本 中請專利範圍第i項之通式⑽酿基胍衍生物或二Π 鹽，以及醫藥上可接受的賦形劑，稀釋劑或載劑j P 12. 根據申請專利範圍第1 1項之醫藥組合 1 ° 治療絕血。 物’其係用於藥物 —-------『裳------訂------j (請先閲讀背面之注意事項再填寫本頁) 經濟部中央揉率局負工消費合作社印製 -5- 本紙張尺度適用中國國家揉準（CNS )六4洗格（210X297公釐） 42667 3, 第86100385號專利申請案 中文申請專利範圍（89年11月) A8 BS C8 D8
    申請專利範圍 公 本 1 ·—種通式（I)之^·衍 修正
    z. -B
    (l) 其中 R々RrSOr ; A指
    N— {請先聞讀背面之注意事項再填寫本頁} .裝 ;〇仏 B指選自（-CHr)A-CO-之群，其中a代表丨至4間之整數； R2指選自下示之群：CN6••烷基， 苯基’其視需要被選自CN 4 -烷氧基，羥基，鹵素， 卣-Cw烷基，二.Cw-烷胺基，二-q.4-烷胺基 烷基，及CU4-烷基之群所取代， 呋喃基，其視需要可被一個CV4-烷基取代’ ρ塞吩基，说峻基，？比p各基， 為基’其視需要可被一個齒素取代’ 及-NR5^6， R3指(^.4-烷基； r5指cN4-烷基； r6指cv4-烷基》 本紙張尺度適用中國國家楯準（CNS ) A4規格（210X297公釐） -訂. 經濟部中央標準局貞工消費合作社印装
TW086100385A 1996-01-16 1997-01-15 Novel benzoylguanidine derivatives, processes for preparing them and their use in the preparation of pharmaceutical compositions TW426673B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19601303A DE19601303A1 (de) 1996-01-16 1996-01-16 Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
TW426673B true TW426673B (en) 2001-03-21

Family

ID=7782846

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086100385A TW426673B (en) 1996-01-16 1997-01-15 Novel benzoylguanidine derivatives, processes for preparing them and their use in the preparation of pharmaceutical compositions

Country Status (27)

Country Link
US (1) US6114335A (zh)
EP (1) EP0882031A1 (zh)
JP (1) JP2000503309A (zh)
KR (1) KR19990077304A (zh)
CN (1) CN1072663C (zh)
AR (1) AR005468A1 (zh)
AU (1) AU722619B2 (zh)
BG (1) BG102623A (zh)
BR (1) BR9707002A (zh)
CA (1) CA2240075A1 (zh)
CO (1) CO4761058A1 (zh)
CZ (1) CZ225398A3 (zh)
DE (1) DE19601303A1 (zh)
EE (1) EE9800200A (zh)
HK (1) HK1016981A1 (zh)
HU (1) HUP9900584A3 (zh)
IL (1) IL124779A0 (zh)
NO (1) NO311517B1 (zh)
NZ (1) NZ326347A (zh)
PL (1) PL327854A1 (zh)
RU (1) RU2181720C2 (zh)
SK (1) SK282751B6 (zh)
TR (1) TR199801328T2 (zh)
TW (1) TW426673B (zh)
UA (1) UA48214C2 (zh)
WO (1) WO1997026253A1 (zh)
ZA (1) ZA97277B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
JP2000219674A (ja) * 1999-01-29 2000-08-08 Daiichi Radioisotope Labs Ltd 新規アラルキルグアニジン化合物
ES2290091T3 (es) * 2000-11-30 2008-02-16 The Children's Medical Center Corporation Sintesis de enantiomeros de 4-amino-talidomida.
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10204989A1 (de) * 2002-02-07 2003-08-21 Aventis Pharma Gmbh Dihydro-thia-phenanthren-carbonyl-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ554068A (en) * 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
PL2380887T3 (pl) * 2005-06-30 2014-01-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
US8642278B2 (en) * 2005-11-22 2014-02-04 University Of South Florida Inhibition of cell proliferation
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2011527677A (ja) * 2008-07-08 2011-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｈｅ−１阻害剤として有用なピロリジニル及びピペリジニル化合物
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
EP2817300B1 (en) 2012-02-21 2018-04-25 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59305042D1 (de) * 1992-09-22 1997-02-20 Hoechst Ag Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
ES2129485T3 (es) * 1992-12-02 1999-06-16 Hoechst Ag Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
TW250477B (zh) * 1992-12-15 1995-07-01 Hoechst Ag
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4404183A1 (de) * 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine

Also Published As

Publication number Publication date
DE19601303A1 (de) 1997-07-17
AU1442997A (en) 1997-08-11
SK282751B6 (sk) 2002-12-03
CN1072663C (zh) 2001-10-10
BR9707002A (pt) 1999-07-20
ZA97277B (en) 1997-07-16
CN1208409A (zh) 1999-02-17
WO1997026253A1 (de) 1997-07-24
NZ326347A (en) 2001-03-30
CO4761058A1 (es) 1999-04-27
NO311517B1 (no) 2001-12-03
HUP9900584A3 (en) 2001-01-29
AU722619B2 (en) 2000-08-10
JP2000503309A (ja) 2000-03-21
NO983261L (no) 1998-07-15
KR19990077304A (ko) 1999-10-25
HUP9900584A2 (hu) 1999-07-28
BG102623A (en) 1999-03-31
NO983261D0 (no) 1998-07-15
HK1016981A1 (en) 1999-11-12
CA2240075A1 (en) 1997-07-24
IL124779A0 (en) 1999-01-26
TR199801328T2 (xx) 1998-10-21
SK95798A3 (en) 1999-01-11
AR005468A1 (es) 1999-06-23
EE9800200A (et) 1998-12-15
PL327854A1 (en) 1999-01-04
CZ225398A3 (cs) 1998-12-16
UA48214C2 (uk) 2002-08-15
EP0882031A1 (de) 1998-12-09
RU2181720C2 (ru) 2002-04-27
US6114335A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
TW426673B (en) Novel benzoylguanidine derivatives, processes for preparing them and their use in the preparation of pharmaceutical compositions
ES2299236T3 (es) Utilizacion de compuestos fenilazobencenicos cationicos en tincion de las fibras queratinicas, composiciones tintoreas y procedimientos de tincion.
HUP0300567A2 (hu) Eljárás új piperazinszármazékok elżállítására
NZ514477A (en) Adamantane derivatives
RU2002107203A (ru) Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos)
JP2006519818A5 (zh)
CY1108792T1 (el) Παραγωγα διοξανιου-2-αλκυλκαρβαμικου, η παρασκευη τους και η εφαρμογη τους στην θεραπευτικη αγωγη
US3694138A (en) Dyeing human hair with n,n-diaryl alkylenediamine oxidation dye compositions
BR112014003245B1 (pt) Composto de ácido n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil] acetamida metanossulfônico monohidratado cristalino, método para a sintetização do mesmo, e composição farmacêutica contendo o mesmo
JP3204972B2 (ja) 新規サリドマイド誘導体、その製造方法並びにこれを薬剤として使用する方法
BR112015008389B1 (pt) Compostos úteis na síntese de compostos de benzamida
JP2012500819A5 (zh)
JPH03130294A (ja) １つのｎ―ヒドロキシアルキル基を導入したベタイン基含有シロキサン化合物
CN102702171B (zh) 多元碱化合物的酸加成盐的制造方法
JP2000204026A (ja) ケラチン繊維の染色におけるカチオン性のジベンゼン性ニトロ化合物の用途、染色用組成物及び染色方法
JP2011529907A5 (ja) イソホスホルアミドマスタードの塩およびその類似体の合成および製剤
MXPA04003935A (es) Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato.
JP3043461B2 (ja) アルケニルメチルヒドロキシプロピルセルロースエーテルおよびそれらの製造方法
HUP0301695A2 (hu) Eljárás [(aril-acetil)-amino]-tiazolok előállítására
JP2015512381A5 (zh)
JP2002520313A5 (zh)
JP2672277B2 (ja) ５位が硫黄で置換された２−ニトロ−ｐ−フェニレンジアミン類とその製法ならびにそれを用いた染色組成物
JPH0211542A (ja) プロパンアミン誘導体
CN110698442B (zh) 一种富马酸地洛昔醇的制备方法
US2695293A (en) N, n'-substituted diamine compounds and method of making the same

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees